Logo: to the web site of Uppsala University

uu.sePublications from Uppsala University
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Risk of venous thromboembolism after SARS-CoV-2 vaccination - evidence from genome-wide association study and population-based observational study
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Clinical pharmacogenomics and osteoporosis. Department of Drug Safety, Swedish Medical Products Agency, Uppsala, Sweden.. (Clinical pharmacogenomics)ORCID iD: 0000-0002-7631-7376
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Clinical pharmacogenomics and osteoporosis. Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Disciplinary Domain of Medicine and Pharmacy, research centers etc., Uppsala Clinical Research Center (UCR).ORCID iD: 0000-0002-2152-4343
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Clinical pharmacogenomics and osteoporosis. Clinical Immunology and Transfusion Medicine, Karolinska University Hospital, Stockholm, Sweden..ORCID iD: 0000-0003-1143-1431
Show others and affiliations
2026 (English)In: British Journal of Clinical Pharmacology, ISSN 0306-5251, E-ISSN 1365-2125, Vol. 92, no 9, p. 3246-3256Article in journal (Refereed) Published
Abstract [en]

Aim: We aimed to investigate whether genetic variation is associated with venous thromboembolism after immunization with SARS-CoV-2 vaccines.

Methods: We conducted a genome-wide association study (GWAS) on cases of venous thromboembolism within 42 days after SARS-CoV-2 vaccination, recruited from reports of adverse drug reactions sent to the Swedish Medical Products Agency. Two hundred one cases (43% women, 91% Swedish) were compared with 4891 Swedish population controls. Analyses were performed on two candidate variants in coagulation factor II (rs1799963) and coagulation factor V (rs6025), on 14 prespecified candidate genes and across the whole genome. To support the findings, we conducted an observational register study of the Swedish general population with/without a diagnosis of thrombophilia and the risks of venous thromboembolism after SARS-CoV-2 vaccination.

Results: In the GWAS, the main findings were that the candidate variants of coagulation factors II rs1799963 and V rs6025 were significantly associated with venous thromboembolism (odds ratio [OR] 2.4 [95% confidence interval (CI) 1.2–4.8], p = .015 and OR 1.8 [95% CI 1.3–2.6], p = .0022). No genetic marker passed the significance threshold in the candidate gene analysis or the full genome-wide analysis. In the register study, people with a thrombophilia diagnosis had a five-fold elevated risk of venous thromboembolism within 42 days after vaccination, adjusted for potential confounders, OR 5.06 [95% CI 3.98–6.44].

Conclusion: Well-characterized genetic variants in the genes of coagulation factors II and V were associated with thromboembolism after SARS-CoV-2 immunization. Further research is recommended to elucidate their potential role in vaccine-related thromboembolic events.

Place, publisher, year, edition, pages
John Wiley & Sons, 2026. Vol. 92, no 9, p. 3246-3256
National Category
Clinical Medicine
Identifiers
URN: urn:nbn:se:uu:diva-581103DOI: 10.1002/bcp.70614ISI: 001776728000001Scopus ID: 42204965OAI: oai:DiVA.org:uu-581103DiVA, id: diva2:2042755
Part of project
Strategic initiative in pharmacogenetics: from discovery to implementation, Swedish Research CouncilThe epidemiology, immunology and genetics of adverse reactions to COVID-19 vaccines, Swedish Research CouncilInnovative tools in precision medicine to understand and predict immune-mediated and haematological adverse drug reactions, Swedish Research CouncilBig Data-Powered End User Function Development (BIG FUN), Vinnova
Funder
The Swedish Brain Foundation, FO2020-0234Swedish Heart Lung Foundation, 20200777The Swedish Stroke AssociationScience for Life Laboratory, SciLifeLabKnut and Alice Wallenberg Foundation, 2021.0010Knut and Alice Wallenberg Foundation, 2020-0040Erik, Karin och Gösta Selanders FoundationUppsala UniversityForte, Swedish Research Council for Health, Working Life and Welfare, 2024-01711Swedish Research Council FormasKnut and Alice Wallenberg Foundation, 2020.0182Knut and Alice Wallenberg Foundation, 2020.0241Knut and Alice Wallenberg Foundation, 2021-0010/VC2021.0018Knut and Alice Wallenberg Foundation, 2020.0299/VC 2022.0008Available from: 2026-03-02 Created: 2026-03-02 Last updated: 2026-09-14Bibliographically approved
In thesis
1. Genetic and clinical risk factors for adverse drug reactions: Pharmacogenomic and pharmacoepidemiological studies of bleeding and thrombosis
Open this publication in new window or tab >>Genetic and clinical risk factors for adverse drug reactions: Pharmacogenomic and pharmacoepidemiological studies of bleeding and thrombosis
2026 (English)Doctoral thesis, comprehensive summary (Other academic)
Abstract [en]

Background There is considerable interindividual variation in drug response and the risk of adverse drug reactions. This variation may be due to several factors, including genetic predisposition and clinical characteristics.

Aim To use pharmacogenomic and pharmacoepidemiological approaches to identify risk factors for the adverse reactions thrombosis and bleeding during treatment with direct oral anticoagulants (DOACs), and venous thromboembolism (VTE) following Covid-19 vaccination.

Methods Study I examined how genetic variation influences the pharmacokinetics of apixaban by analysing data from a pivotal clinical trial using both a genome-wide association study (GWAS) and candidate gene analyses. Study II evaluated a methodology for identifying clinical risk factors for DOAC-induced bleeding using a pharmacovigilance database. In Study III, a GWAS was conducted in patients who experienced bleeding during DOAC therapy to identify genetic risk factors. Study IV combined a GWAS with pharmacoepidemiological analyses to identify risk factors for developing VTE after Covid-19 vaccination.

Results In Study I, genetic variation in the drug transporter gene ABCG2 was associated with the pharmacokinetics of apixaban. However, the effect of ABCG2 on drug exposure was modest and not associated with bleeding or thromboembolic events. The methodology evaluated in Study II identified several established and some novel potential risk factors for bleeding during DOAC treatment. Study III revealed that genetic variation in the genes BAIAP2L2, CYP3A5, ABCG2, and VWF may be associated with bleeding in DOAC-treated patients. In Study IV, individuals with well-characterised genetic variants in coagulation factor V (Leiden, rs6025) or factor II (prothrombin, rs1799963) exhibited higher risk of VTE within 42 days following Covid-19 vaccination. A large population-based health register study further showed that people diagnosed with these congenital thrombophilias had five times higher risk of VTE within 42 days after vaccination.

Conclusion This thesis highlights the complementary roles of pharmacogenomics and pharmacoepidemiology in post-marketing drug safety surveillance. Although further studies are required, the results contribute important knowledge towards the prevention of adverse drug reactions.

Place, publisher, year, edition, pages
Uppsala: Acta Universitatis Upsaliensis, 2026. p. 61
Series
Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine, ISSN 1651-6206 ; 2259
Keywords
Pharmacovigilance, Pharmacogenomics, Pharmacogenetics, Genome-Wide Association Study, Pharmacoepidemiology, Direct Oral Anticoagulants (DOACs), Covid-19 Vaccines, Haemorrhage, Venous Thromboembolism, Drug-Related Side Effects and Adverse Reactions, Adverse Drug Reactions
National Category
Clinical Medicine
Research subject
Medical Science
Identifiers
urn:nbn:se:uu:diva-581107 (URN)978-91-513-2802-7 (ISBN)
Public defence
2026-05-27, Sal IV, Universitetshuset, Biskopsgatan 3, Uppsala, 13:00 (English)
Opponent
Supervisors
Available from: 2026-04-29 Created: 2026-03-27 Last updated: 2026-04-29

Open Access in DiVA

fulltext(752 kB)90 downloads
File information
File name FULLTEXT01.pdfFile size 752 kBChecksum SHA-512
c27403e18ab1f5dcdcf66f1c12a34db5e98235f408091a15da7e8d300cc5cbc639da127feff2610cbb4ad99cef5c46ab6b745c4b8674136d6fcdf7ba4d7166af
Type fulltextMimetype application/pdf

Other links

Publisher's full textScopus

Authority records

Attelind, SofiaEriksson, NiclasCavalli, MarcoSundström, AndersWadelius, MiaHallberg, Pär

Search in DiVA

By author/editor
Attelind, SofiaEriksson, NiclasCavalli, MarcoXu, YiyiNyberg, FredrikSundström, AndersWadelius, MiaHallberg, Pär
By organisation
Clinical pharmacogenomics and osteoporosisUppsala Clinical Research Center (UCR)Department of Pharmacy
In the same journal
British Journal of Clinical Pharmacology
Clinical Medicine

Search outside of DiVA

GoogleGoogle Scholar
Total: 90 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
urn-nbn

Altmetric score

doi
urn-nbn
Total: 59 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf